



Grant Thornton

**Glenmark Pharmaceuticals
Distribution s.r.o.**

REPORT

**ON THE AUDIT
OF FINANCIAL STATEMENTS
AS AT 31 MARCH, 2022**



CONTENTS

- **Independent Auditor's Report**
- **Financial Statement and Annual Report as at 31.03.2022**

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. The Annual report and the Notes were not translated. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

INDEPENDENT AUDITOR'S REPORT

To the Shareholder and Management of

Glenmark Pharmaceuticals Distribution s.r.o.

Registered Address: Hvězdova 1716/2b, Nusle, 140 00 Praha 4

Company Identification Number (IČ): 047 27 339

Auditor's Opinion

We have audited the accompanying financial statements of Glenmark Pharmaceuticals Distribution s.r.o. (hereinafter also the "Company") prepared in accordance with accounting principles generally accepted in the Czech Republic, showing a balance sheet total of 787.686 thds. CZK and a profit of 9.313 thds. CZK. These financial statements comprise the balance sheet as at 31 March, 2022, and the income statement, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 31 March, 2022 and of its financial performance and its cash flows for the year then ended in accordance with accounting principles generally accepted in the Czech Republic.

Basis for Opinion

We conducted our audit in accordance with the Act on Auditors, and Auditing Standards of the Chamber of Auditors of the Czech Republic, which are International Standards on Auditing (ISAs), as amended by the related application clauses. Our responsibilities under these laws and regulations are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Act on Auditors and the Code of Ethics adopted by the Chamber of Auditors of the Czech Republic and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information presented in the Annual Report

In compliance with Section 2(b) of the Act on Auditors, other information comprises the information included in the Annual Report other than the financial statements and auditor's report thereon. Managing Directors is responsible for the other information.

Our opinion on the financial statements does not cover the other information. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. In addition, we assess whether the other information has been prepared,

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. The Annual report and the Notes were not translated. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

in all material aspects, in accordance with applicable law or regulation, in particular, whether the other information complies with law or regulation in terms of formal requirements and procedure for preparing the other information in the context of materiality, i.e. whether any non-compliance with these requirements could influence judgements made on the basis of the other information.

Based on the procedures performed, to the extent we are able to assess it, we report that:

- The other information describing the facts that are also presented in the financial statements is, in all material aspects, consistent with the financial statements; and
- The other information is prepared in compliance with applicable law or regulation.

In addition, our responsibility is to report, based on the knowledge and understanding of the Company obtained in the audit, that the other information does not contain any material misstatement of fact. Based on the procedures we have performed on the other information obtained, we have not identified any material misstatement of fact.

Responsibilities of the Company's Managing Directors (hereinafter also "Company's statutory body") for the Financial Statements

Company's statutory body is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the Czech Republic and for such internal control as the statutory body determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Company's statutory body is responsible for assessing the Company's ability to continue as a going concern, disclosing in the notes to the financial statements, as applicable, matters related to going concern and using the going concern basis of accounting unless the Company's statutory body either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the above mentioned regulations will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the above law or regulation, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. The Annual report and the Notes were not translated. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Company's statutory body in the notes to the financial statements.
- Conclude on the appropriateness of the statutory body's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Company's statutory body and regarding, among other matters, the planned scope and timing of the audit and our significant audit findings, including any significant deficiencies identified in the internal controls.



Grant Thornton Audit s.r.o.

Pujmanové 1753/10a, 140 00 Praha 4 - Nusle

Licence No. 603

Ing. Petra Digitálně podepsal
Kopsová Ing. Petra Kopsová
Datum: 2022.05.24
15:16:50 +02'00'

Ing. Petra Kopsová
Auditor, Licence No. 2459

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. The Annual report and the Notes were not translated. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

**Financial statements and Annual Report
for the year ended 31.3.2022**

Name of accountancy unit: Glenmark Pharmaceuticals Distribution s.r.o.
Seat: Hvězdova 1716/2b
 Praha 4
 14000
Identif. Code: 04727339
Compiled on: 7.5.2022

Components of the Financial Statements:

Balance Sheet
 Profit and Loss Statement
 Statement of changes in Equity
 Cash Flow Statement
 Notes to the Financial Statements
 Annual Report including a Report on relationships

Name of statutory body or individual, who is an accounting unit:	Signature
Andrzej Gondek	Andrzej Sylwester Gondek <small>Elektronicznie podpisany przez Andrzej Sylwester Gondek Data: 2022.05.24 15:00:32 +02'00'</small>
Person responsible for financial statements (Name)	Signature
Jana Neradová	Ing. Jana Neradová <small>Digitálně podepsal Ing. Jana Neradová Datum: 2022.05.24 09:05:22 +02'00'</small>

BALANCE SHEET
in full scale
as of 31.3.2022
(in entire thousands CZK)

Identif. Code:
04727339

Name and seat
of accountability unit
Glenmark Pharmaceuticals
Distribution s.r.o.
Hvězdova 1716/2b
Praha 4
14000

Denotation a	A S S E T S b	Current accounting period			Previous acc. period
		Brutto 1	Correction 2	Netto 3	Netto 4
	TOTAL ASSETS	982 964	= 195 278	787 686	618 477
A.	Amounts receivable for subscribed registered capital				
B.	Fixed assets	470 478	= 190 578	279 900	310 486
B. I.	Long-term intangible assets	4 566	= 3 231	1 335	1 664
B. I. 1.	Intangible results of development				
B. I. 2.	Valuable rights (patents, licences and know-how)	4 566	= 3 231	1 335	1 664
B. I. 2.1.	Software	2 394	= 1 499	895	1 092
B. I. 2.2.	Other valuable rights (patents, licences and know-how)	2 172	= 1 732	440	572
B. I. 3.	Goodwill				
B. I. 4.	Other long-term intangible assets				
B. I. 5.	Advances for intangible fixed assets and intangible fixed assets under construction				
B. I. 5.1.	Advances for long-term intangible assets				
B. I. 5.2.	Intangible fixed assets under construction				
B. II.	Long-term tangible assets	465 912	= 187 347	278 565	308 822
B. II. 1.	Land and structures				
B. II. 1.1.	Land				
B. II. 1.2.	Structures				
B. II. 2.	Plant and equipment	6 766	= 3 696	3 070	2 167
B. II. 3.	Goodwill, incl. market value increment	459 128	= 183 651	275 477	306 085
B. II. 4.	Other long-term tangible assets				
B. II. 4.1.	Forests, orchards etc.				
B. II. 4.2.	Full-grown animals and their herds				
B. II. 4.3.	Other long-term tangible assets				
B. II. 5.	Advances for tangible fixed assets and tangible fixed assets under construction	18		18	570
B. II. 5.1.	Advances for tangible fixed assets				31
B. II. 5.2.	Long-term tangible assets in progress	18		18	539
B. III.	Long-term financial assets				
B. III. 1.	Equity investments - group undertakings				
B. III. 2.	Loans - controlled and controlling organizations				
B. III. 3.	Equity investments - associated companies				
B. III. 4.	Loans - associated companies				
B. III. 5.	Other long-term securities and equity investments				
B. III. 6.	Loans - other				
B. III. 7.	Other long-term investments				
B. III. 7.1.	Other long-term investments				
B. III. 7.2.	Advances for long-term financial assets				

Denotation a	A S S E T S b	Current accounting period			Previous acc. period
		Brutto 1	Correction 2	Netto 3	Netto 4
C.	Current assets	512 012	- 4 700	507 312	307 260
C I	Inventories	285 900	- 4 700	281 200	139 541
C I. 1	Materials				
C I. 2	Work-in-progress and semi-finished products				
C I. 3	Finished goods and goods for resale	285 900	- 4 700	281 200	139 541
C I. 3.1	Finished goods				
C I. 3.2	Purchased goods for resale (inc. goods in transit)	285 900	- 4 700	281 200	139 541
C I. 4	Young and other animals and their herds				
C I. 5	Advance payments for inventories				
C II	Receivables	182 313		182 313	127 566
C II. 1	Long-term receivables	1 342		1 342	1 232
C II. 1.1	Trade receivables				
C II. 1.2	Inter-group receivables (controlled or controlling entity)				
C II. 1.3	Inter-group receivables - significant influence				
C II. 1.4	Deferred tax receivable	1 326		1 326	1 232
C II. 1.5	Receivables - other	16		16	
C II. 1.5.1	Receivables from partners				
C II. 1.5.2	Long-term advances granted	16		16	
C II. 1.5.3	Estimated receivables				
C II. 1.5.4	Other receivables				
C II. 2	Short-term receivables	180 971		180 971	126 334
C II. 2.1	Trade receivables	178 488		178 488	125 946
C II. 2.2	Inter-group receivables (controlled or controlling entity)				
C II. 2.3	Inter-group receivables - significant influence				
C II. 2.4	Receivables - other	2 483		2 483	388
C II. 2.4.1	Receivables from partners				
C II. 2.4.2	Social security and health insurance				
C II. 2.4.3	Due from state - tax receivables				
C II. 2.4.4	Short-term advances granted	2 230		2 230	96
C II. 2.4.5	Estimated receivables				
C II. 2.4.6	Other receivables	253		253	292
C III	Short-term financial assets				
C III. 1	Equity investments - group undertakings				
C III. 2	Other short-term financial assets				
C IV	Cash	43 799		43 799	40 153
C IV. 1	Cash in hand				
C IV. 2	Bank accounts	43 799		43 799	40 153
D I	Accruals	474		474	731
D I. 1	Prepaid expenses	474		474	731
D I. 2	Complex prepaid expenses				
D I. 3	Accrued income				

Denotation a	EQUITY + LIABILITIES b	Current acc period 5	Previous acc period 6
	TOTAL EQUITY + LIABILITIES	787 686	618 477
A.	Equity	540 260	530 947
A. I	Registered capital	10 000	10 000
A. I. 1	Registered capital	10 000	10 000
A. I. 2	Own shares/ownership interests (-)		
A. I. 3	Changes in registered capital		
A. II	Premium and capital funds	590 000	590 000
A. II. 1	Share premium		
A. II. 2	Capital funds	590 000	590 000
A. II. 2.1	Other capital funds	590 000	590 000
A. II. 2.2	Valuation differences from re-valuation of assets and liabilities (+/-)		
A. II. 2.3	Differences from revaluation in transformation of companies (+/-)		
A. II. 2.4	Differences from transformation of companies (+/-)		
A. II. 2.5	Differences from valuation in transformation of companies (+/-)		
A. III	Funds from earnings		
A. III. 1	Other reserve funds		
A. III. 2	Statutory and other funds		
A. IV	Retained profit or loss from prior year (+/-)	- 69 053	- 76 002
A. IV. 1	Retained earnings or losses (+/-)	- 69 053	- 76 002
A. IV. 2	Other profit or loss from previous years (+/-)		
A. V	Profit or loss of the current accounting period (+/-)	9 313	6 949
A. VI	Approved advance profit distribution (-)		
B. + C.	Liabilities	246 484	86 437
B	Provisions	2 632	2 290
B. I	Provision for pensions and similar liabilities		
B. II	Provision for income tax		
B. III	Provisions made according to special legal regulations		
B. IV	Other provisions	2 632	2 290

Denotation a	EQUITY + LIABILITIES b	Current acc. period 5	Previous acc. period 6
C.	Liabilities	243 852	84 147
C I	Long-term liabilities		
C I 1	Issued bonds		
C I 1 1	Convertible debentures and bonds		
C I 1 2	Other debentures and bonds		
C I 2	Liabilities to credit institutions		
C I 3	Long-term advances received		
C I 4	Trade payables		
C I 5	Long-term promissory notes		
C I 6	Inter-group payables (controlled or controlling entity)		
C I 7	Inter-group payables - significant influence		
C I 8	Deferred tax payable		
C I 9	Liabilities - other		
C I 9.1	Payables to partners		
C I 9.2	Estimated payables		
C I 9.3	Other payables		
C II	Short-term liabilities	243 852	84 147
C II 1	Issued bonds		
C II 1 1	Convertible debentures and bonds		
C II 1 2	Other debentures and bonds		
C II 2	Liabilities to credit institutions		
C II 3	Short-term advances received		
C II 4	Trade payables	183 523	32 606
C II 5	Short-term bills of exchange payable		
C II 6	Inter-group payables (controlled or controlling entity)		
C II 7	Inter-group payables - significant influence		
C II 8	Liabilities - other	60 329	51 541
C II 8.1	Payables to partners		
C II 8.2	Other short-term borrowings		
C II 8.3	Payables to employees	3 935	3 470
C II 8.4	Social security and health insurance payables	2 358	2 059
C II 8.5	Due to state - taxes and subsidies	6 960	7 438
C II 8.6	Estimated payables	47 054	38 532
C II 8.7	Other payables	22	42
D.	Accruals	942	1 093
D I	Accrued expenses	942	1 093
D II	Deferred income		

PROFIT AND LOSS STATEMENT - classification by types

in full scale
as of 31.3.2022
(in entire thousands CZK)

Name and seat
of accountancy unit
Glenmark Pharmaceuticals
Distribution s.r.o.
Hvězdova 1716/2b
Praha 4
14000

Identif. Code:
04727339

Denotation a	TEXT b	Accounting period	
		Current 1	Previous 2
I.	Revenue from products and services	268 998	272 368
II.	Sales of goods bought for resale	414 795	339 972
*	Total sales	683 793	612 340
A.	Purchased consumables and services	532 896	477 502
A. 1.	Cost of goods sold	444 061	402 507
A. 2.	Consumables	5 653	6 613
A. 3.	Services	83 182	68 382
B.	Change in inventory of own production (+/-)		
C.	Own work capitalized (-)		
D.	Staff costs	89 506	83 008
D. 1.	Wages and salaries	66 808	61 557
D. 2.	Social security, health insurance and other expenses	22 698	21 451
D. 2. 1.	Social security and health insurance expenses	21 049	19 523
D. 2. 2.	Other expenses	1 649	1 928
E.	Adjustments relating to operating activities	33 148	31 794
E. 1.	Adjustments to intangible and tangible fixed assets	32 972	32 665
E. 1. 1.	Depreciation and amortization of intangible and tangible fixed assets	32 972	32 665
E. 1. 2.	Impairment of intangible and tangible fixed assets		
E. 2.	Adjustments to inventories	176	- 865
E. 3.	Adjustments to receivables		- 6
III.	Other operating revenues	248 143	182 683
III. 1.	Proceeds from disposals of fixed assets	30	3
III. 2.	Proceeds from disposals of raw materials		
III. 3.	Other operating revenues	248 113	182 680
F.	Other operating expenses	259 516	189 770
F. 1.	Net book value of fixed assets sold	45	7
F. 2.	Material sold		
F. 3.	Taxes and charges	188	142
F. 4.	Provisions relating to operating activity and complex prepaid expenses	342	332
F. 5.	Other operating expenses	258 941	189 289
*	Operating profit or loss (+/-)	16 870	12 949

Denotation a	TEXT b	Accounting period	
		Current 1	Previous 2
IV.	Revenue from long-term investments - equity investments		
IV. 1.	Revenue from equity investments - group undertakings		
IV. 2.	Other revenue from equity investments		
G.	Cost of equity investments sold		
V.	Revenue from other long-term investments		
V. 1.	Revenue from other long-term investments - group undertakings		
V. 2.	Other revenue from other long-term investments		
H.	Expenses related to other long-term investments		
VI.	Interest revenue and similar revenue		
VI. 1.	Interest revenue and similar revenue - group undertakings		
VI. 2.	Other interest revenue and similar revenue		
I.	Adjustments and provisions relating to financial activity		
J.	Interest expense and similar expense	526	499
J. 1.	Interest expense and similar expense - group undertakings		67
J. 2.	Other interest expense and similar expense	526	432
VII.	Other financial revenues	59	290
K.	Other financial expenses	1 918	1 130
*	Profit (loss) from financial operations	- 2 385	- 1 339
**	Profit (loss) before tax (+/-)	14 485	11 610
L.	Income tax	5 172	4 661
L. 1.	Current tax	5 267	61
L. 2.	Deferred tax (+/-)	- 95	4 600
**	Profit (loss) after tax (+/-)	9 313	6 949
M.	Transfer of profit or loss to shareholders/members (+/-)		
***	Profit (loss) for the accounting period (+/-)	9 313	6 949
*	Net turnover for the accounting period = I. + II. + III. + IV. + V. + VI. +	931 995	795 313

**STATEMENT OF
CHANGES IN EQUITY**

as of 31.3.2022
(in entire thousands CZK)

Identif. Code:
143727339

Name and seat
of accountability unit
Glenmark Pharmaceuticals
Distribution s.r.o.
Hvězdova 1716/2b
Praha 4
14000

	Share capital	Own shares/ ownership interest (-)	Share premium	Other capital funds	Difference from revaluation	Differences from transformation	Funds from profit, reserve fund	Retained earnings or losses (+/-)	Other profit or loss from previous years	Profit or loss for the current period	TOTAL EQUITY
Balance at 31.3.2020	10 000			590 000				-76 532		530	523 998
Distribution of profit or loss								530		-530	
Change in share capital											
Profit shares paid											
Profit share payments declined											
Changes in capital funds											
Profit or loss for the current period										6 949	6 949
Balance at 31.3.2021	10 000			590 000				-76 002		6 949	530 947
Distribution of profit or loss								6 949		-6 949	
Change in share capital											
Profit shares paid											
Profit share payments declined											
Changes in capital funds											
Profit or loss for the current period										9 313	9 313
Balance at 31.3.2022	10 000			590 000				-69 053		9 313	540 260

CASH FLOW STATEMENT

as of 31.3.2022
(in entire thousands CZK)

Identif. Code:
04727339

Name and seat
of accountancy unit
Glenmark Pharmaceuticals
Distribution s.r.o.
Hvězdova 1716/2b
Praha 4
14000

Den. a	TEXT b	Balance in accounting period	
		current 1	previous 2
P.	Cash and cash equivalents, beginning of period	40 153	23 628
	Net operating cash flow	-	-
Z.	Accounting profit (loss) from ordinary activities	14 485	11 610
A. 1.	Non-cash transactions	34 031	32 629
1. 1.	Depreciation of fixed assets	32 972	32 665
2.	Change in:	518	- 539
2. 1.	goodwill and adjustments to acquired assets		
2.	provisions and other adjustments	518	- 539
3.	Profit(-) Loss(+) on sale of fixed assets	15	4
4.	Profit(-) Loss(+) on sale of securities		
5.	Revenue from dividends and profit distribution		
6.	Expense and revenue interests accounted for	526	499
7.	Other non-cash transactions		
A. *	Net operating cash flow before financial items, changes in working capital and extraordinary items	48 516	44 239
A. 2.	Changes in working capital	- 41 944	- 25 447
2. 1.	Change in receivables from operating activities and deferrals	- 54 396	101 432
2.	Change in short-term liabilities from operating activities and accruals	154 287	- 102 144
3.	Change in inventories	- 141 835	- 24 735
4.	Change in short-term financial assets, other than cash and cash equivalents		
A. **	Net operating cash flow before financial balances, tax and extraordinary items	6 572	18 792
A. 3.	Interest paid excluding amounts capitalised	- 526	- 784
A. 4.	Interest received		
A. 5.	Income tax paid on ordinary income and income tax relating to prior periods		
A. 6.	Dividends received		
A. ***	Net operating cash flow	6 046	18 008

Den. a	TEXT b	Balance in accounting period	
		current 1	previous 2
	Investment activity	-	-
B. 1.	Acquisition of fixed assets	- 2 430	- 1 486
1. 1.	Acquisition of tangible fixed assets	- 1 655	- 1 486
2.	Acquisition of intangible fixed assets	- 775	
3.	Acquisition of long-term investments		
B. 2.	Proceeds from sales of fixed assets	30	3
2. 1.	Proceeds from sales of tangible and intangible fixed assets	30	3
2.	Proceeds from sale of financial investments		
B. 3.	Advances and loans to related parties		
B. ***	Net cash flow from investment activity	- 2 400	- 1 483
	Financial activity	-	-
C. 1.	Change in long-term liabilities and bank loans		
C. 2.	Increase and decrease in equity from cash transactions		
2. 1.	Subscription of shares and investments, even. Funds from earnings		
2.	Equity paid to shareholders		
3.	Other cash contributions from partners and shareholders		
4.	Loss settlement from partners		
5.	Payments from funds created from net profit		
6.	Dividends paid, including withholding tax paid		
C. ***	Net cash flow from financial activity		
F.	Net increase or decrease in cash balance	3 646	16 525
R.	Cash and cash equivalents, end of period	43 799	40 153

NOTES TO THE FINANCIAL STATEMENTS
as of March 31, 2022

Glenmark Pharmaceuticals Distribution s.r.o.

Registered address: Hvězdova 1716/2b, 140 00 Praha 4

Legal status: Limited Liability Company

ID: 04727339